Stockscreener 앱 받기
1.23
7.52%
-0.10
시간 외 거래:
1.23
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
ADC Therapeutics Strengthens Team with Major Equity Incentive Package - Stock Titan
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - MarketBeat
HC Wainwright Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire
ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK
Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates - MSN
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - StreetInsider.com
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market - MSN
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics Q4 Net Income USD -30.727 Million - MarketScreener
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Finan - GuruFocus
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue By Investing.com - Investing.com South Africa
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue - Investing.com
ADC THERAPEUTICS SA -REDH Earnings Results: $ADCT Reports Quarterly Earnings - Nasdaq
A Preview Of ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation a - GuruFocus
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 – Company Announcement - Financial Times
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Bought by Platinum Investment Management Ltd. - MarketBeat
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 - BioSpace
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financ - GuruFocus
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA® - Business Wire
ADC Therapeutics Sets Date for Crucial Year-End 2024 Financial Update - Stock Titan
Antibody Drug Conjugates Market to Witness Massive Growth - openPR
WuXi XDC and AbTis collaborate for antibody-drug conjugates - Pharmaceutical Technology
ADC THERAPEUTICS SA -REDH Earnings Preview: Recent $ADCT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Cantor Fitzgerald Reiterates "Overweight" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying? - Simply Wall St
Cantor Fitzgerald Reiterates “Overweight” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Projected to Post Earnings on Wednesday - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - MSN
ADC Therapeutics (ADCT) to Release Earnings on Wednesday - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Stephens Analyst Says - MarketBeat
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - Armenian Reporter
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 at Stephens - Defense World
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR
Is Adc Therapeutics SA (ADCT) a good investment opportunity? - US Post News
1.20%
1.60%
자본화:
|
볼륨(24시간):